codrituzumab
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 9, 2021 (NCT04928677)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Glypican-3INHIBITOR
Glypican-3 inhibitor
- Ganglioside GD3OTHER
Ganglioside GD3 other
Interacts with CD16/Fc gamma RIIIa and triggers antibody-dependent cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
- Glypican-3ADCC
GPC3
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298089 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04928677 | Phase 1 | Jun 9, 2021 | Chugai, Memorial Sloan-Kettering Cancer Center |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chugai | For profit | 1 | 0 | 1 | 2021 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1